This site is intended for US healthcare professionals

This site is intended for US healthcare professionals

Take a natural route to docetaxel therapy

  • Beizray is the first and only FDA approved docetaxel injection to be mixed with albumin before administration

  • Established efficacy of docetaxel, free of synthetic solvents like PS-80 or PEG300.1,4
    Hypersensitivity reactions and injection related adverse events can occur from docetaxel itself and may potentially be exacerbated by synthetic solvents, such as PS-80, impacting treatment consistency.*1,5

  • Beizray has demonstrated bioequivalence to Taxotere® and uses albumin, the body’s most abundant carrier protein, to transport docetaxel1–3

*Beizray contains a Boxed WARNING for hypersensitivity reactions, and there is insufficient data demonstrating the incidence or severity of these will be lower with Beizray than with other docetaxel formulations.

Albumin: the body’s most abundant carrier protein3

Albumin is the most abundant protein in human blood plasma, produced by the liver, and plays essential roles in maintaining fluid balance, nourishing tissues, and transporting hormones, vitamins and drugs.3

Most abundant protein in the blood plasma3

Over 50% of all plasma
proteins

Multifunctional Protein

Acts as a stabilizer, antioxidant, and carrier6,7

Antioxidant Properties

Helps provide protection against oxidation – reducing oxidation of model proteins7,8

  • Synthesized by hepatocytes3
  • Maintains intravascular oncotic pressure3
  • Carries hormones, ions, and medications3

Human serum albumin has gained prominence
as a drug delivery platform6

Albumin-based anticancer drugs are efficiently
used in cancer therapy due to their ability
to target gp60 receptors.6

Dosage Forms and Strengths1

BEIZRAYTM (docetaxel) injection is a clear, colorless liquid supplied as follows:

NDC: 70710-2093-4

BEIZRAY 160 mg kit1

Consisting of the following:

  • Two single-dose vials of BEIZRAY:
    80 mg/4 mL each; a clear and colorless liquid
  • One single-dose vial of IV Solution Stabilizer: 50 mL of 25% Albumin Human USP solution for infusion; a clear and slightly viscous solution

NDC: 70710-2091-3

BEIZRAY 80 mg kit1

Consisting of the following:

  • One single-dose vial of BEIZRAY:
    80 mg/4 mL; a clear and colorless liquid
  • One single-dose vial of IV Solution Stabilizer: 50 mL of 25% Albumin Human USP solution for infusion; a clear and slightly viscous solution

NDC: 70710-2092-8

BEIZRAY 20 mg/mL vial1

Consisting of the following:

  • One single-dose vial of BEIZRAY:
    20 mg/mL; a clear and colorless liquid
Order now

INDICATIONS AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID
RETENTION

  • Treatment-related mortality associated with BEIZRAY is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive BEIZRAY as a single agent at a dose of 100 mg/m2.
  • Avoid the use of BEIZRAY in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN.Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death.Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia.Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of BEIZRAY.
  • Do not administer BEIZRAY to patients with neutrophil counts of <1500 cells/mm3. Monitor blood counts frequently as neutropenia may be severe and result in infection.
  • Do not administer BEIZRAY to patients who have a history of severe hypersensitivity reactions to BEIZRAY.Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the BEIZRAY infusion and administration of appropriate therapy.
  • Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).
Image